At present, the medicine is being tested in two clinics of St. Petersburg.
Clinical tests of a new drug to treat COVID-19 complications have started in St. Petersburg. The medicine developed by Biocad is being tested in Botkin Hospital and Almazov Medical Center to treat patients in severe condition.
60 people have been given the innovative therapy. Only two of them had to be taken to resuscitation department, 13 have been able to leave hospital in satisfactory condition.
On Wednesday, Vice Governor Oleg Ergashev visited the production facility of the developer company.
Oleg Ergashev told: ‘I have asked the chief doctor of Botkin Hospital to study the drug and recommend the period when it should be used. I am sure that we can bring the mortality rate in hospitals down.’
Dmitry Morozov, Managing Director of Biocad, explained: ‘It will be two syringes in a box, just two injections under the skin. I hope this will prevent patients from developing grave conditions that require resuscitation.’
Preliminary studies show that patients who receive this therapy stay in hospital 7-8 days less than other patients. The drug is expected to registered in late May – early June.